Synergo by Medical Enterprises Group

Therapeutic Area(s):
Urology, Oncology
Company Status:
Regulatory Approval, Revenue Growth

Company at a Glance

Medical Enterprises Group, founded in 1998, develops innovative minimally invasive technologies providing benefits for both patients and healthcare systems.

Our group consists of professional staff and leaders in the field of physics, engineering and clinical experts

The lead product, Synergo® RITE (Radiofrequency-Induced ThermoChemotherapeutic Effect) offers clinically effective, safe and easy way to deliver the tri-modality local, non-ionizing Radiofrequency radiation, chemotherapy and deep tissue hyperthermia targeted at the tissue by microwave (RF) energy.

Technology & Product(s)

The Synergo® System is a minimally invasive technology used for the treatment of intermediate and high-risk non-muscle invasive bladder cancer. The treatment combines microwave (RF) deep tissue hyperthermia with instillation of chemotherapeutic drug. Application specific software monitors and records treatment parameters during treatment session and provides a user-friendly interface.
A sterile triple lumen, silicone, transurethral Foley catheter is used for the drug intravesical instillation. The catheter is equipped with RF minutarised antenna that radiates the bladder walls, causing phenotypical changes selectively in cancerous cells, creates membrane micro-poring and metabolic changes in these cells to increase the uptake of the drug, enhances drug mobility, and generates heat at the target tissue at the desired, controlled temperature (hyperthermia) which is a synergistic protagonist. 5 thermocouples incorporated inside the catheter monitor bladder wall and urethra temperatures in real time during treatment.

Synergo® treatment is local and performed on an out-patient basis and is successfully given routinely to patients in leading medical centers around the world.

Over 40 published articles and clinical trials have been conducted since 1995 proving its safety and efficacy. The treatment reduces recurrences and the need for repetitive surgical interventions, as well as the need for radical operation of bladder removal, radiotherapy and/or expensive systemic treatments.

About 70% of the patients who have been treated with Synergo® after failing other treatments remain disease-free (no tumor recurrence) for at least 24 months compared to 20-30% when treating patients with other instillations without Synergo®.

Synergo® technology is CE certified since 2001, has been included in the European Urological Guidelines as the only proven device to treat non-muscle invasive bladder cancer and is now in the process of obtaining approval from the U.S. Food and Drug Administration (FDA).


Objectives: Distributors
Target businesses: Medical device companies
Target Countries: Germany, Austria, UK, Italy, Spain, Poland, Japan, Singapore, S. Korea, S. Africa, Canada, Australia, Brazil